Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Presentation TCT 2024

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Presenter: David Kwon

October 29, 2024

TCT 555: NIRS-Detected Lipid-Rich Plaques are Highly Responsive to Novel Escalated LDL-C Reduction Therapy

Presentation TCT 2023

TCT 555: NIRS-Detected Lipid-Rich Plaques are Highly Responsive to Novel Escalated LDL-C Reduction Therapy

Presenter: Karlis Trusinskis

October 25, 2023

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

Log-linear association per unit change in LDL-C and the risk of CV disease-a statin tale

Presentation JIM 2019

Log-linear association per unit change in LDL-C and the risk of CV disease-a statin tale

Presenter: Bernardo Cortese

February 15, 2019

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Presentation Controversies and Advances 2017

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Presenter: Sanjay Kaul

November 16, 2017

The LDL Hypothesis Post FOURIER: Heading Home From ODYSSEY

Presentation TCT 2017

The LDL Hypothesis Post FOURIER: Heading Home From ODYSSEY

Presenter: Bernard J. Gersh, Robert A. Harrington, Wolfgang Koenig

October 30, 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.